Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug904 | Chloroquine Wiki | 0.38 |
| drug2552 | Nitazoxanide Wiki | 0.26 |
| drug2029 | Ivermectin Wiki | 0.21 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.
Description: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Death.
Measure: Change in Clinical status of subject on a 7-point ordinal scale Time: Week 2Description: PCR for SARS-CoV-2 in pharyngeal swab
Measure: PCR test Time: Week 2 and Week 4Description: Occurrence of supplemental Oxygen
Measure: Supplemental Oxygen Time: Week 2 and Week 4Description: Occurrence of Mechanical Ventilation
Measure: Mechanical Ventilation Time: Week 2 and Week 4Description: Occurence of Adverse events
Measure: Incidence of Treatment-Emergent Adverse Events Time: Week 2 and Week 4Description: Inflammatory Biomarker
Measure: C-reactive protein (CRP) Time: Week 2 and Week 4Description: Inflammatory Biomarker
Measure: Interleukin 6 (IL-6) Time: Week 2 and Week 4Description: Inflammatory Biomarker
Measure: D-dimer Time: Week 2 and Week 4Description: type II class of interferons
Measure: Interferon gamma Time: Week 2 and Week 4Description: proteins
Measure: Ferritin Time: Week 2 and Week 4Description: Inflammatory Biomarker
Measure: TNF alpha Time: Week 2 and Week 4Description: Inflammatory Biomarker
Measure: Interleukin 1-β Time: Week 2 and Week 4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports